If you stop taking semaglutide after losing weight, you’re likely to gain most of it back—staying on the medication is key to keeping the weight off.
Claim Context
Weight loss achieved with semaglutide 2.4 mg is maintained over 68 weeks only if treatment is continued; discontinuation leads to significant weight regain (mean +6.9% from Week 20 to Week 68).
“STEP 4: From Week 20 to Week 69, -7.9% with continued semaglutide vs. +6.9% in those switched to placebo (treatment difference, -14.8%; p<0.001).”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
The pooled magnitude of weight regain after discontinuation of semaglutide 2.4 mg across all withdrawal trials, compared to continued therapy.
A systematic review and meta-analysis of all RCTs with withdrawal phases comparing weight change after stopping semaglutide 2.4 mg versus continuing it, including STEP 4 and any future trials, with primary outcome: weight change from end of treatment to 12–24 months post-discontinuation.
Causal effect of discontinuation on weight regain after semaglutide-induced weight loss.
A double-blind RCT of 400+ adults who achieved ≥10% weight loss on semaglutide 2.4 mg over 20 weeks, randomized to continue semaglutide or switch to placebo for 48 additional weeks, with primary outcome: percent weight change from Week 20 to Week 68.
Real-world patterns of weight regain after stopping semaglutide 2.4 mg in clinical practice.
A prospective cohort study of 1000+ patients who discontinued semaglutide 2.4 mg after ≥6 months of use, tracking weight change monthly for 2 years, with data on reasons for discontinuation and alternative interventions.
Association between weight regain and specific patient factors (e.g., baseline insulin resistance, behavioral habits).
A case-control study comparing 200 patients who regained >80% of lost weight after stopping semaglutide to 400 who maintained ≥80% loss, assessing baseline metabolic markers, eating behaviors, and psychological factors.
Consensus on whether semaglutide should be considered a lifelong therapy for obesity.
A consensus panel of obesity specialists and health policy experts evaluating evidence on weight regain, cost, and long-term safety to develop guidelines on duration of semaglutide therapy.